Dr. Vlock on Anti—CD20 Interleukin-2 Immunocytokine in NHL

Daniel R. Vlock, MD
Published: Monday, Dec 14, 2015



Daniel R. Vlock, MD, founder and CEO, Alopexx Enterprises, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Clinical research on this study began with a previous, similar study conducted by City of Hope researchers, Vlock explains, where the immunocytokine was administered intravenously. Vlock explains that, in this phase I/II study, subcutaneous injection of the immunocytokine was administered.

Sixteen patients were treated in the study. The maximum tolerated dose has yet to be determined, Vlock adds. There were also no dose-limited toxicities observed in patients. Thirteen of the 16 patients were evaluable for response, and 12 patients achieved a clinical benefit.



Daniel R. Vlock, MD, founder and CEO, Alopexx Enterprises, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Clinical research on this study began with a previous, similar study conducted by City of Hope researchers, Vlock explains, where the immunocytokine was administered intravenously. Vlock explains that, in this phase I/II study, subcutaneous injection of the immunocytokine was administered.

Sixteen patients were treated in the study. The maximum tolerated dose has yet to be determined, Vlock adds. There were also no dose-limited toxicities observed in patients. Thirteen of the 16 patients were evaluable for response, and 12 patients achieved a clinical benefit.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x